Michael Wandell

1.5k total citations · 1 hit paper
16 papers, 1.1k citations indexed

About

Michael Wandell is a scholar working on Pathology and Forensic Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael Wandell has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Michael Wandell's work include Genetic factors in colorectal cancer (4 papers), Colorectal Cancer Screening and Detection (4 papers) and Cancer Genomics and Diagnostics (3 papers). Michael Wandell is often cited by papers focused on Genetic factors in colorectal cancer (4 papers), Colorectal Cancer Screening and Detection (4 papers) and Cancer Genomics and Diagnostics (3 papers). Michael Wandell collaborates with scholars based in United States and Germany. Michael Wandell's co-authors include Timothy R. Church, Dale C. Snover, David F. Ransohoff, Neal Osborn, Shannon R. Payne, Thomas Rösch, Robert Day, Catherine Lofton–Day, Brent A. Blumenstein and Steven J. Mongin and has published in prestigious journals such as Gastroenterology, PEDIATRICS and Gut.

In The Last Decade

Michael Wandell

16 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer

2013 575 citations Timothy R. Church, Michael Wandell et al. Gut profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Wandell United States	12	560	369	345	317	298	16	1.1k
T Horie Japan	10	247 0.4×	159 0.4×	100 0.3×	85 0.3×	87 0.3×	35	801
E.J. Mark United States	16	280 0.5×	653 1.8×	71 0.2×	348 1.1×	205 0.7×	49	1.3k
Petra Schrotz‐King Germany	21	670 1.2×	255 0.7×	195 0.6×	391 1.2×	272 0.9×	67	1.3k
María Buxó Spain	15	196 0.3×	185 0.5×	112 0.3×	286 0.9×	248 0.8×	75	872
Dai Zhang China	14	257 0.5×	162 0.4×	98 0.3×	340 1.1×	211 0.7×	65	1.1k
James Bristol United Kingdom	17	345 0.6×	130 0.4×	183 0.5×	75 0.2×	98 0.3×	31	799
Ying-Nan Wang China	6	505 0.9×	223 0.6×	116 0.3×	464 1.5×	447 1.5×	6	1.8k
Seok Hyun Kim South Korea	17	151 0.3×	233 0.6×	56 0.2×	135 0.4×	79 0.3×	86	809
Katie Quinn United States	10	185 0.3×	183 0.5×	62 0.2×	186 0.6×	178 0.6×	37	664
Colleen Pelser United States	11	337 0.6×	48 0.1×	94 0.3×	87 0.3×	80 0.3×	16	828

Countries citing papers authored by Michael Wandell

Since Specialization

Citations

This map shows the geographic impact of Michael Wandell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wandell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wandell more than expected).

Fields of papers citing papers by Michael Wandell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wandell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wandell. The network helps show where Michael Wandell may publish in the future.

Co-authorship network of co-authors of Michael Wandell

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wandell. A scholar is included among the top collaborators of Michael Wandell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wandell. Michael Wandell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Day, Robert W., Michael Wandell, Brent A. Blumenstein, et al.. (2020). Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. UNC Libraries. 23 indexed citations

Ladabaum, Uri, John M. Allen, Michael Wandell, & Scott D. Ramsey. (2013). Colorectal Cancer Screening with Blood-Based Biomarkers: Cost-Effectiveness of Methylated Septin 9 DNA versus Current Strategies. Cancer Epidemiology Biomarkers & Prevention. 22(9). 1567–1576. 66 indexed citations

Church, Timothy R., Michael Wandell, Catherine Lofton–Day, et al.. (2013). Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 63(2). 317–325. 575 indexed citations breakdown →

Payne, Shannon R., Timothy R. Church, Michael Wandell, et al.. (2013). Endoscopic Detection of Proximal Serrated Lesions and Pathologic Identification of Sessile Serrated Adenomas/Polyps Vary on the Basis of Center. Clinical Gastroenterology and Hepatology. 12(7). 1119–1126. 117 indexed citations

Huckins, David S., Harold K. Simon, Karen Copeland, et al.. (2013). A novel biomarker panel to rule out acute appendicitis in pediatric patients with abdominal pain. The American Journal of Emergency Medicine. 31(9). 1368–1375. 39 indexed citations

Ladabaum, Uri, John I. Allen, Michael Wandell, & Scott Ramsey. (2011). Screening for Colorectal Cancer With a Blood Test: Projected Effectiveness and Cost-Effectiveness of a Novel Plasma Methylated Septin-9 DNA (mSEPT9) Assay. Gastroenterology. 140(5). S–50. 1 indexed citations

Church, Timothy R., et al.. (2010). Prospective clinical validation of an assay for methylated SEPT9 DNA for use in detection of colorectal cancer in human plasma from average risk men and women over the age of 50. Zeitschrift für Gastroenterologie. 48(8). 1 indexed citations

Church, Timothy R., Michael Wandell, Catherine Lofton–Day, et al.. (2010). Prospective Clinical Validation of an Assay for Methylated SEPT9 DNA in Human Plasma as a Colorectal Cancer Screening Tool in Average Risk Men and Women ≥50 Years. Gastroenterology. 139(1). e18–e18. 11 indexed citations

Wandell, Michael, et al.. (2001). Detection of Hepatitis C Antibody With At-Home Collection Kits Using an Innovative Laboratory Algorithm. Infectious Diseases in Clinical Practice. 10(9). 474–480. 8 indexed citations

10.

Wandell, Michael, et al.. (1997). Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation.. PubMed. 157(3). 309–14. 44 indexed citations

11.

Handsfield, H. Hunter, Michael Wandell, Laura H. Goldstein, & K Shriver. (1987). Screening and diagnostic performance of enzyme immunoassay for antibody to lymphadenopathy-associated virus. Journal of Clinical Microbiology. 25(5). 879–884. 19 indexed citations

12.

Vožeh, S., R. Tyler Hillman, Michael Wandell, Thomas M. Ludden, & Lewis B. Sheiner. (1985). Computer-Assisted Drug Assay Interpretation Based on Bayesian Estimation of Individual Pharmacokinetics. Therapeutic Drug Monitoring. 7(1). 66–73. 20 indexed citations

13.

Jackson, J. Edward, et al.. (1981). Cimetidine decreases theophylline clearance.. PubMed. 123(6). 615–7. 68 indexed citations

14.

Wandell, Michael, J. Robert Powell, W Hager, et al.. (1980). Effect of quinine on digoxin kinetics. Clinical Pharmacology & Therapeutics. 28(4). 425–430. 24 indexed citations

15.

Wandell, Michael, et al.. (1977). Dextromethorphan toxicity: reversal by naloxone.. PubMed. 59(1). 117–8. 32 indexed citations

16.

Wandell, Michael, et al.. (1977). Dextromethorphan Toxicity: Reversal by Naloxone. PEDIATRICS. 59(1). 117–118. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact